137 related articles for article (PubMed ID: 23141895)
1. Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro.
Serfaty L
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S53-60. PubMed ID: 23141895
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid and chemoprevention of colorectal cancer.
Serfaty L; Bissonnette M; Poupon R
Gastroenterol Clin Biol; 2010 Oct; 34(10):516-22. PubMed ID: 20609543
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development.
Wali RK; Stoiber D; Nguyen L; Hart J; Sitrin MD; Brasitus T; Bissonnette M
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1316-21. PubMed ID: 12433708
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.
Khare S; Mustafi R; Cerda S; Yuan W; Jagadeeswaran S; Dougherty U; Tretiakova M; Samarel A; Cohen G; Wang J; Moore C; Wali R; Holgren C; Joseph L; Fichera A; Li YC; Bissonnette M
Nutr Cancer; 2008; 60(3):389-400. PubMed ID: 18444174
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.
Carey EJ; Lindor KD
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S61-4. PubMed ID: 23141896
[TBL] [Abstract][Full Text] [Related]
6. Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.
Loddenkemper C; Keller S; Hanski ML; Cao M; Jahreis G; Stein H; Zeitz M; Hanski C
Int J Cancer; 2006 Jun; 118(11):2750-7. PubMed ID: 16385573
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
Alberts DS; Martínez ME; Hess LM; Einspahr JG; Green SB; Bhattacharyya AK; Guillen J; Krutzsch M; Batta AK; Salen G; Fales L; Koonce K; Parish D; Clouser M; Roe D; Lance P;
J Natl Cancer Inst; 2005 Jun; 97(11):846-53. PubMed ID: 15928305
[TBL] [Abstract][Full Text] [Related]
8. Treatment of NASH with ursodeoxycholic acid: pro.
Ratziu V
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
10. Opposing effects of bile acids deoxycholic acid and ursodeoxycholic acid on signal transduction pathways in oesophageal cancer cells.
Abdel-Latif MM; Inoue H; Reynolds JV
Eur J Cancer Prev; 2016 Sep; 25(5):368-79. PubMed ID: 26378497
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of colorectal cancer: a role for ursodeoxycholic acid, folate and hormone replacement treatment?
Solimando R; Bazzoli F; Ricciardiello L
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):555-68. PubMed ID: 22122771
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of colorectal cancer.
Das D; Arber N; Jankowski JA
Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
[TBL] [Abstract][Full Text] [Related]
14. Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers.
van Gorkom BA; van der Meer R; Boersma-van Ek W; Termont DS; de Vries EG; Kleibeuker JH
Scand J Gastroenterol; 2002 Aug; 37(8):965-71. PubMed ID: 12229974
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
[TBL] [Abstract][Full Text] [Related]
16. Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.
Lim SC; Duong HQ; Choi JE; Lee TB; Kang JH; Oh SH; Han SI
Carcinogenesis; 2011 May; 32(5):723-31. PubMed ID: 21362627
[TBL] [Abstract][Full Text] [Related]
17. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
18. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.
Thompson PA; Wertheim BC; Roe DJ; Ashbeck EL; Jacobs ET; Lance P; Martínez ME; Alberts DS
Cancer Prev Res (Phila); 2009 Dec; 2(12):1023-30. PubMed ID: 19952360
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.
Qiao L; Yacoub A; Studer E; Gupta S; Pei XY; Grant S; Hylemon PB; Dent P
Hepatology; 2002 Apr; 35(4):779-89. PubMed ID: 11915023
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice.
Kohno H; Suzuki R; Yasui Y; Miyamoto S; Wakabayashi K; Tanaka T
Clin Cancer Res; 2007 Apr; 13(8):2519-25. PubMed ID: 17438113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
